INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Background Immunotherapies targeting immune checkpoint inhibitors have revolutionized cancer treatment but are limited by incomplete patient responses. Costimulatory agonists like OX40 (CD134), a tumor necrosis factor receptor family member critical for T-cell survival and differentiation, have show...

Full description

Saved in:
Bibliographic Details
Main Authors: William L Redmond, Yoshinobu Koguchi, Melissa J Kasiewicz, Annah S Rolig, Nisha Holay, Bryan Becklund, Anya Polovina, Sae Jeong Ahn, Brendan P Eckelman, Rashi Yadav, Thi Staebler, Noah D Simons, Yaiza Diaz de Durana
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e011524.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e011524.full

Similar Items